These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15269145)

  • 1. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma.
    Bates SE; Bakke S; Kang M; Robey RW; Zhai S; Thambi P; Chen CC; Patil S; Smith T; Steinberg SM; Merino M; Goldspiel B; Meadows B; Stein WD; Choyke P; Balis F; Figg WD; Fojo T
    Clin Cancer Res; 2004 Jul; 10(14):4724-33. PubMed ID: 15269145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).
    Bates S; Kang M; Meadows B; Bakke S; Choyke P; Merino M; Goldspiel B; Chico I; Smith T; Chen C; Robey R; Bergan R; Figg WD; Fojo T
    Cancer; 2001 Sep; 92(6):1577-90. PubMed ID: 11745237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.
    Chico I; Kang MH; Bergan R; Abraham J; Bakke S; Meadows B; Rutt A; Robey R; Choyke P; Merino M; Goldspiel B; Smith T; Steinberg S; Figg WD; Fojo T; Bates S
    J Clin Oncol; 2001 Feb; 19(3):832-42. PubMed ID: 11157037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi.
    Chen CC; Meadows B; Regis J; Kalafsky G; Fojo T; Carrasquillo JA; Bates SE
    Clin Cancer Res; 1997 Apr; 3(4):545-52. PubMed ID: 9815718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine.
    Braybrooke JP; Vallis KA; Houlbrook S; Rockett H; Ellmén J; Anttila M; Ganesan TS; Harris AL; Talbot DC
    Cancer Chemother Pharmacol; 2000; 46(1):27-34. PubMed ID: 10912574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine.
    Abraham J; Edgerly M; Wilson R; Chen C; Rutt A; Bakke S; Robey R; Dwyer A; Goldspiel B; Balis F; Van Tellingen O; Bates SE; Fojo T
    Clin Cancer Res; 2009 May; 15(10):3574-82. PubMed ID: 19417029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
    Samuels BL; Hollis DR; Rosner GL; Trump DL; Shapiro CL; Vogelzang NJ; Schilsky RL
    Clin Cancer Res; 1997 Nov; 3(11):1977-84. PubMed ID: 9815587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic study of infusional valspodar.
    Ma MK; McLeod HL; Westervelt P; Fracasso PM
    J Clin Pharmacol; 2002 Apr; 42(4):412-8. PubMed ID: 11936566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2.
    Smith NF; Mani S; Schuetz EG; Yasuda K; Sissung TM; Bates SE; Figg WD; Sparreboom A
    Ann Pharmacother; 2010 Nov; 44(11):1709-17. PubMed ID: 20959500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia.
    Tidefelt U; Liliemark J; Gruber A; Liliemark E; Sundman-Engberg B; Juliusson G; Stenke L; Elmhorn-Rosenborg A; Möllgård L; Lehman S; Xu D; Covelli A; Gustavsson B; Paul C
    J Clin Oncol; 2000 May; 18(9):1837-44. PubMed ID: 10784624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin.
    Kovarik JM; Rigaudy L; Guerret M; Gerbeau C; Rost KL
    Clin Pharmacol Ther; 1999 Oct; 66(4):391-400. PubMed ID: 10546923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.
    Wong M; Balleine RL; Blair EY; McLachlan AJ; Ackland SP; Garg MB; Evans S; Farlow D; Collins M; Rivory LP; Hoskins JM; Mann GJ; Clarke CL; Gurney H
    J Clin Oncol; 2006 Jun; 24(16):2448-55. PubMed ID: 16651648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma.
    Small EJ; Frye JW; Wilkinson MJ; Carroll PR; Ernest ML; Stagg RJ
    Cancer; 1994 Jun; 73(11):2803-7. PubMed ID: 8194022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist.
    Lush RM; Meadows B; Fojo AT; Kalafsky G; Smith HT; Bates S; Figg WD
    J Clin Pharmacol; 1997 Feb; 37(2):123-8. PubMed ID: 9055138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
    Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
    Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.
    O'Brien MM; Lacayo NJ; Lum BL; Kshirsagar S; Buck S; Ravindranath Y; Bernstein M; Weinstein H; Chang MN; Arceci RJ; Sikic BI; Dahl GV
    Pediatr Blood Cancer; 2010 May; 54(5):694-702. PubMed ID: 20209646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.
    Boote DJ; Dennis IF; Twentyman PR; Osborne RJ; Laburte C; Hensel S; Smyth JF; Brampton MH; Bleehen NM
    J Clin Oncol; 1996 Feb; 14(2):610-8. PubMed ID: 8636778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite.
    Fischer V; Rodríguez-Gascón A; Heitz F; Tynes R; Hauck C; Cohen D; Vickers AE
    Drug Metab Dispos; 1998 Aug; 26(8):802-11. PubMed ID: 9698296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma.
    Warner E; Tobe SW; Andrulis IL; Pei Y; Trachtenberg J; Skorecki KL
    Am J Clin Oncol; 1995 Jun; 18(3):251-6. PubMed ID: 7747714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined treatment with low-dose interferon plus vinblastine is associated with less toxicity than conventional interferon monotherapy in patients with metastatic renal cell carcinoma.
    Tsavaris N; Skarlos D; Bacoyiannis C; Aravantinos G; Kosmas C; Retalis G; Panopoulos C; Vadiaka M; Dimitrakopoulos A; Kostantinidis K; Mitropoulos D; Bougas D; Pantazopoulos D; Kosmidis P
    J Interferon Cytokine Res; 2000 Aug; 20(8):685-90. PubMed ID: 10954911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.